Lymph Node

Chapter

Abstract

This chapter provides information about immunohistochemical (IHC) studies used in diagnosing specific hematolymphoid neoplasms in an up-to-date and easy-to-use format for the busy pathologist. It lists the most useful IHC markers of lymphoid and histiocytic/dendritic neoplasms based on new WHO classification of tumors of hematopoietic and lymphoid tissue (2008). The second edition of this chapter is to add new antibodies for B-cell lymphoma which enhance the probability for diagnosis or can act as an alternate marker in unusual cases, in which a B-cell lymphoma does not present with characteristic immunohistochemical staining. Prognostic markers are also presented which allow better management of patients with specific B cell lymphomas. Most recent general information about IHC markers used in hematopoietic neoplasms is listed in Table 30.1. When a lymph node biopsy is suspected to have a hematopoietic neoplasm, the frequently used markers are presented in Table 30.2. Tables 30.3, 30.4, 30.5, and 30.6 illustrate the IHC markers including new immunohistochemical markers used for the differential diagnoses of mature B-cell lymphomas, mature T-cell lymphomas and lymphoid neoplasms with blastic morphology. IHC markers helpful in lymphomas may also be expressed in non-hematopoietic neoplasms; these are explained in Table 30.8. Other tables focus on the IHC markers used for specific lymphoid or histiocytic/dendritic neoplasms. We hope that this chapter will be useful in diagnosing and in differentiating hematopoietic neoplasms.

Keywords

B-cell lymphoma T-cell lymphoma NK-cell lymphoma Histiocytic and dendritic cell neoplasm Immunodeficiency-associated lymphoproliferative disorders Follicular lymphoma Marginal zone lymphoma Mantle cell lymphoma Small lymphocytic lymphoma/chronic lymphocytic leukemia Diffuse large B-cell lymphoma Anaplastic large cell lymphoma Hodgkins lymphoma 

References

  1. 1.
    Lester SC. Special studies. In: Lester SC. editor. Manual of surgical pathology. 2nd edn. Philadelphia, PA: Elsevier; 2006. p 71–170.Google Scholar
  2. 2.
    Higgins RA, Blankenship JE, Kinney MC. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med. 2008;132(3):441–61.PubMedGoogle Scholar
  3. 3.
    Chaiwatanatorn K, Stamaratis G, Opeskin K, Firkin F, Nandurkar H. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab. Leuk Lymphoma. 2009;50(10):1666–75.PubMedCrossRefGoogle Scholar
  4. 4.
    Tandon B, Peterson L, Gao J, et al. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol. 2011;24(11):1433–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Erdfelder F, Hertweck M, Filipovich A, Uhrmacher S, Kreuzer KA. High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia. Hematol Rep. 2010;2(1):e3.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Farren TW, Giustiniani J, Liu FT, et al. Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood. 2011;118(8):2174–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Palumbo GA, Parrinello N, Fargione G, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. 2009;33(9):1212–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in B cell-derived neoplasms. Am J Clin Pathol. 2010;134(5):726–33.PubMedCrossRefGoogle Scholar
  9. 9.
    El Desoukey NA, Afify RA, Amin DG, Mohammed RF. CD200 expression in B-cell chronic lymphoproliferative disorders. J Investig Med. 2012;60(1):56–61.PubMedGoogle Scholar
  10. 10.
    Alapat D, Coviello-Malle J, Owens R, et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol. 2012;137(1):93–100.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Kretz-Rommel A, Bowdish KS. Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression. Expert Opin Biol Ther. 2008;8(1):5–15.PubMedCrossRefGoogle Scholar
  12. 12.
    van den Brand M, van Krieken JH. Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A Syst Rev Haematol. 2013;98(7):1003–13.Google Scholar
  13. 13.
    Kanellis G, Roncador G, Arribas A, et al. Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia. 2009;23(10):1847–57.PubMedCrossRefGoogle Scholar
  14. 14.
    Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051–8.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Ogura G, Kikuti YY, Kikuchi T, Carreras J, Sato T, Nakamura N. MYD88 (L265P) mutation in malignant lymphoma using formalin-fixed paraffin-embedded section. J Clin Exp Hematop. 2013;53(2):175–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013;121(22):4504–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826–33.PubMedCrossRefGoogle Scholar
  18. 18.
    Ondrejka SL, Lin JJ, Warden DW, Durkin L, Cook JR, Hsi ED. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol. 2013;140(3):387–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Falini B, Agostinelli C, Bigerna B, et al. IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology. 2012;61(5):930–41.PubMedCrossRefGoogle Scholar
  20. 20.
    Younes SF, Beck AH, Ohgami RS, et al. The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow. Am J Clin Pathol. 2011;135(5):697–708.PubMedCrossRefGoogle Scholar
  21. 21.
    Chapman-Fredricks J, Younes SF, Fan YS, Sandoval-Sus JD, Natkunam Y, Lossos IS. Usefulness of HGAL and LMO2 immunohistochemistry in the identification of follicular lymphomas of the non-gastric gastrointestinal tract. Appl Immunohistochem Mol Morphol. 2013;21(3):200–4.PubMedGoogle Scholar
  22. 22.
    Dyhdalo KS, Lanigan C, Tubbs RR, Cook JR. Immunoarchitectural patterns of germinal center antigens including LMO2 assist in the differential diagnosis of marginal zone lymphoma vs follicular lymphoma. Am J Clin Pathol. 2013;140(2):149–54.PubMedCrossRefGoogle Scholar
  23. 23.
    Marafioti T, Copie-Bergman C, Calaminici M, et al. Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. Histopathology. 2013;62(6):860–75.PubMedCrossRefGoogle Scholar
  24. 24.
    Montes-Moreno S, Roncador G, Maestre L, et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood. 2008;111(1):351–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Paterson MA, Hosking PS, Coughlin PB. Expression of the serpin centerin defines a germinal center phenotype in B-cell lymphomas. Am J Clin Pathol. 2008;130(1):117–26.PubMedCrossRefGoogle Scholar
  26. 26.
    Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555–62.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Zeng W, Fu K, Quintanilla-Fend L, Lim M, Ondrejka S, Hsi ED. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol. 2012;36(2):214–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Gradowski JF, Sargent RL, Craig FE, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression. Am J Clin Pathol. 2012;138(1):132–9.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Ferrando AA. SOX11 is a mantle cell lymphoma oncogene. Blood. 2013;121(12):2169–70.PubMedCrossRefGoogle Scholar
  30. 30.
    Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B, Kimby E, Sander B. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2013;119(18):4215–23.CrossRefGoogle Scholar
  31. 31.
    Kondratiev S, Duraisamy S, Unitt CL, et al. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. Am J Surg Pathol. 2011;35(10):1531–9.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Tapia G, Lopez R, Muñoz-Mármol AM, et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology. 2011;59(4):672–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, Møller MB. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol. 2012;36(4):612–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One. 2012;7(4):e33813.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Gupta M, Maurer MJ, Wellik LE, et al. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood. 2012;120(22):4400–6.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Gonin J, Larousserie F, Bastard C, et al. Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma. PLoS One. 2011;6(9):e24617.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Bedewy AM, Elgammal MM, Bedewy MM, El-Maghraby SM. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin’s lymphoma. Ann Hematol. 2013;92(10):1359–67.PubMedCrossRefGoogle Scholar
  38. 38.
    Tang H, Wei Q, Ge J, et al. IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma. Hum Pathol. 2013;44(10):2167–72.PubMedCrossRefGoogle Scholar
  39. 39.
    Marafioti T, Paterson JC, Ballabio E, et al. The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica. 2010;95(3):432–9.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2011;35(1):76–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Mao Y, Zhang DW, Zhu H, et al. LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL). Diagn Pathol. 2012;7:178.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012;36(12):1796–800.PubMedCrossRefGoogle Scholar
  43. 43.
    Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012;119(1):188–91.PubMedCrossRefGoogle Scholar
  44. 44.
    Akarca AU, Shende VH, Ramsay AD, et al. BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia. Br J Haematol. 2013;162(6):848–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Dabbs DJ. Diagnostic immunohistochemistry. 3rd edn. Philadelphia, PA: Churchill Livingstone Elsevier; 2010. p 274, 308, 405.Google Scholar
  46. 46.
    Muller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 180.Google Scholar
  47. 47.
    Campo E, Catovsky D, Montserrat E, Muller-Hermelink HK, Harris NL, Stein H. B-cell prolymphocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 183.Google Scholar
  48. 48.
    Isaacson PG, Piris MA, Berger F, Swerdlow SH. Splenic B-cell marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 185.Google Scholar
  49. 49.
    Foucar K, Falini B, Catovsky D, Stein H. Hairy cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 188.Google Scholar
  50. 50.
    Chen YH, Tallman MS, Goolsby C, Peterson L. Immunophenotypic variations in hairy cell leukemia. Am J Clin Pathol. 2006;125(5):251–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Piris M, Foucar K, Mollejo M, Campo E, Falini B. Splenic B-cell lymphoma/leukaemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 191.Google Scholar
  52. 52.
    Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood. 2008;111(4):2253–60.PubMedCrossRefGoogle Scholar
  53. 53.
    Swerdlow SH, Berger F, Pileri SA, Harris NL, Jaffe ES, Stein H. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 194.Google Scholar
  54. 54.
    Harris NL, Issacson PG, Grogan TM, Jaffe ES. Heavy chain disease. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 196.Google Scholar
  55. 55.
    McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 200.Google Scholar
  56. 56.
    Isaacson PG, Chott A, Nakamura S, Muller-Hermelink HK, Harris NL. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008. p. 214.Google Scholar
  57. 57.
    Campo E, Pileri SA, Jaffe ES, Muller-Hermelink HK, Nathwani BN. Nodal marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 218.Google Scholar
  58. 58.
    Harris NL, Swerdlow SH, Jaffe ES, Ott G. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 220.Google Scholar
  59. 59.
    Willemze R, Swerdlow SH, Harris NL, Vergier B. Primary cutaneous follicular center lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 227.Google Scholar
  60. 60.
    Swerdlow SH, Campo E, Seto M, Muller-Hermelink HK. Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 229.Google Scholar
  61. 61.
    Sein H, Warnke RA, Chan WC, Jaffe ES, Chang JKC, Gatter KC, Campo E. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 233.Google Scholar
  62. 62.
    De Wolf-Peeters C, Delabie J, Campo E, Jaffe ES, Delsol G. T cell/histiocyte-rich large B cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 238.Google Scholar
  63. 63.
    Kluin PM, Deckert M, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 240.Google Scholar
  64. 64.
    Meijer CJL, Vergier B, Duncan LM, Willemze R. Primary cutaneous DLBCL, leg type. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 242.Google Scholar
  65. 65.
    Nakamura S, Jaffe ES, Swerdlow SH. EBV positive diffuse large B-cell lymphoma of the elderly. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 243.Google Scholar
  66. 66.
    Chan JKC, Aozasa K, Gaulard P. DLBCL associated with chronic inflammation. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 245.Google Scholar
  67. 67.
    Pittaluga S, Wilson WH, Jaffe ES. Lymphomatoid granulomatosis. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 247.Google Scholar
  68. 68.
    Gaulard P, Harris NL, Pileri SA K, et al. Primary mediastinal (thymic) large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 250.Google Scholar
  69. 69.
    Dorfman DM, Shahsafaei A, Alonso MA. Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers. Mod Pathol. 2012;25(12):1637–43.PubMedCrossRefGoogle Scholar
  70. 70.
    Nakamura S, Ponzoni M, Campo E. Intravascular large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 252.Google Scholar
  71. 71.
    Delsol G, Campo E, Gascoyne RD. ALK-positive large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 254.Google Scholar
  72. 72.
    Stein H, Harris NL, Campo E. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 256.Google Scholar
  73. 73.
    Isaacson PG, Campo E, Harris NL. Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 258.Google Scholar
  74. 74.
    Burbelo PD, Issa AT, Ching KH, et al. Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. J Infect Dis. 2010;201(12):1919–22.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Said J, Cesarman E. Primary effusion lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 260.Google Scholar
  76. 76.
    Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 262.Google Scholar
  77. 77.
    Kluin PM, Harris NL, Stein H, Leoncini L. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma, Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 265.Google Scholar
  78. 78.
    Jaffe ES, Stein H, Swerdlow SH, Campo E, Pileri SA, Harris NL. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma, classical Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 267.Google Scholar
  79. 79.
    Catovsky D, Muller-Hermelink HK, Ralfkiaer E. T-cell prolymphocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 270.Google Scholar
  80. 80.
    Chan WC, Foucar K, Morice WG, Catovsky D. T-cell large granular lymphocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 272.Google Scholar
  81. 81.
    Villamor N, Morice WG, Chan WC, Foucar K. Chronic lymphoproliferative disorders of NK cells. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 274.Google Scholar
  82. 82.
    Chan JKC, Jaffe ES, Ralfiaer E, Ko YH. Aggressive NK-cell leukemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 276.Google Scholar
  83. 83.
    Quintanilla-Martines L, Kimura H, Jaffe ES. EBV-positive T-cell lymphoproliferative disorders of childhood. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 278.Google Scholar
  84. 84.
    Ohshima K, Jaffe ES, Kikuchi M. Adult T-cell leukemia/lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 281.Google Scholar
  85. 85.
    Chan JKC, Quintanilla-Martines L, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 285.Google Scholar
  86. 86.
    Isaacson PG, Chott A, Ott G, Stein H. Enteropathy-associated T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 289.Google Scholar
  87. 87.
    Gaulard P, Jaffe ES, Krenacs L, Macon WR. Hepatosplenic T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 292.Google Scholar
  88. 88.
    Jaffe ES, Gaulard P, Rafkiaer E, Cerroni L, Meiher CJLM. Subcutaneous panniculitis-like T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 294.Google Scholar
  89. 89.
    Rafkiaer E, Cerroni L, Sander CA, Smoller BR, Willemze R. Mycosis fungoides. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 296.Google Scholar
  90. 90.
    Ralfkiaer E, Willemze R, Whittaker SJ. Sezary syndrome. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 299.Google Scholar
  91. 91.
    Ralfkiaer E, Willemze R, Pauli M, Kadin ME. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 300.Google Scholar
  92. 92.
    McQuitty E, Curry JL, Tetzlaff MT, Prieto VG, Duvic M, Torres-Cabala C. The differential diagnosis of CD8-positive (“type D”) lymphomatoid papulosis. J Cutan Pathol. 2014;41(2):88–100.PubMedCrossRefGoogle Scholar
  93. 93.
    Bertolotti A, Pham-Ledard AL, Vergier B, Parrens M, Bedane C, Beylot-Barry M. Lymphomatoid papulosis type D: an aggressive histology for an indolent disease. Br J Dermatol. 2013;169(5):1157–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Andersen RM, Skaarup Larsen M, Svenstrup Poulsen T, Falensteen Lauritzen A, Skov L. Lymphomatoid papulosis type D or an aggressive epidermotropic CD8 cytotoxic T-cell lymphoma. Acta Derm Venereol. 2014;94:474–5. doi: 10.2340/00015555-1750.PubMedCrossRefGoogle Scholar
  95. 95.
    Cho-Vega JH, Vega F. CD30-Negative Lymphomatoid papulosis type D in an elderly man. Am J Dermatopathol. 2014;36(2):190–2.PubMedCrossRefGoogle Scholar
  96. 96.
    Robson A, Assaf C, Bagot M, et al. Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features Report of an EORTC Cutaneous Lymphoma Task Force Workshop. Histopathology; 2014. doi: 10.1111/his.12371.Google Scholar
  97. 97.
    Gaulard P, Berti E, Willemze R, Jaffe ES. Primary cutaneous peripheral T-cell lymphoma, rare subtype. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 302.Google Scholar
  98. 98.
    Pilrei SA, Weisenburger DD, Song I, Jaffe ES. Peripheral T-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 306.Google Scholar
  99. 99.
    Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472–9.PubMedCrossRefGoogle Scholar
  100. 100.
    Dogan A, Gaulard P, Jaffe ES, Ralfkiaer E, Muller-Hermelink HK. Angioimmunoblastic T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 309.Google Scholar
  101. 101.
    Delsol G, Falini B, Muller-Hermelink HK, Campo E, Jaffe ES, Gsacoyne RD, Stein H, Kinney MC. Anaplastic large cell lymphoma (ALCL), ALK-positive. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 312.Google Scholar
  102. 102.
    Mason DY, Harris NL, Delsol G, Stein H, Campo E, Kinney MC, Jaffe ES, Falini B. Anaplastic large cell lymphoma (ALCL), ALK-negative. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 317.Google Scholar
  103. 103.
    Poppema S, Delsol G, Pileri SA, Stein H, Swerdlow SH, Warnke RA, Jaffe ES. Nodular lymphocyte predominant Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 323.Google Scholar
  104. 104.
    Stein H, Delsol G, Pileri SA, Weiss LM, Poppema S, Jaffe ES. Classical Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 326.Google Scholar
  105. 105.
    Van Krieken JH, Onciu M, Elenitoba-Johnson KSJ, Jaffe ES. Immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 336.Google Scholar
  106. 106.
    Gaulard P, Swerdlow SH, Harris NL, Jaffe ES, Sundstrom C. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 350.Google Scholar
  107. 107.
    Raphael M, Said J, Borisch B, Cesarman E, Harris NL. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.Google Scholar
  108. 108.
    Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 343.Google Scholar
  109. 109.
    Grogan TM, Pileri SA, Chan JKC, Weiss LM, Fletcher CDM. Histiocytic sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 356.Google Scholar
  110. 110.
    Jaffe R, Weiss LM, Facchetti F. Tumor derived from Langerhans cells. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: 358; 2008.Google Scholar
  111. 111.
    Weiss LM, Grogan TM, Chan JKC. Interdigitating dendritic cell sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 361.Google Scholar
  112. 112.
    Chan JKC, Pileri SA, Delsol G, Fletcher CDM, Weiss LM, Grogan TM. Follicular dendritic cell sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 363.Google Scholar
  113. 113.
    Weiss LM, Chan JKC, Fletcher CDM. Other rare dendritic cell sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 365.Google Scholar
  114. 114.
    Jaffe R, Burgdorf W, Fletcher CDM. Disseminated juvenile xanthogranuloma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 366.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory MedicineGeisinger Health SystemWilkes-BarreUSA
  2. 2.PathologyUniversity of Virginia Health SystemCharlottesvilleUSA

Personalised recommendations